The QualityStocks Daily Thursday, February 23rd, 2023

Today's Top 3 Investment Newsletters

QualityStocks(ATLX) $19.8500 +60.47%

Schaeffer's(AMAM) $6.5300 +43.20%

The Stock Dork(VBLT) $0.1683 +29.66%

The QualityStocks Daily Stock List

Atlas Lithium Corporation (ATLX)

QualityStocks and MarketClub Analysis reported earlier on Atlas Lithium Corporation (ATLX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Atlas Lithium Corporation (OTCQB: ATLX) is a mineral exploration and mining firm that is focused on exploring for and developing lithium, rare earths and titanium projects.

The firm has its headquarters in Beverly Hills, California and was incorporated in 2011, on December 15th. Prior to its name change in October 2022, the firm was known as Brazil Minerals Inc. It operates as part of the other precious metals and mining industry, under the basic materials sector. The firm serves consumers around the globe.

The enterprise is focused on the development and advancement of its 100%-owned hard-rock lithium project known as Minas Gerais Lithium project, which is located in the municipality of Aracuai in the Vale do Jequitinhonha region of the state of Minas Gerais in Brazil. This project is comprised of fifty-two mineral rights spread over 227 km2. The enterprise also has another lithium project located in the Northeastern region of Brazil. It also takes part in gold, iron and quartzite projects via its subsidiaries.

The enterprise has interests in gold through a minority position in Jupiter Gold Corp and in iron through a majority position in Apollo Resources Corp. In addition to this, it owns multiple mining concessions for alluvial diamond, gold and industrial sand. It sells sand for use in construction.

The company, which recently changed its name, is focused on increasing its market value and beginning the production of lithium-concentrate. This will not only generate significant additional revenues for the company but also open it up to new growth opportunities, in addition to extending its global reach.

Atlas Lithium Corporation (ATLX), closed Thursday's trading session at $19.85, up 60.4689%, on 3,763,861 volume. The average volume for the last 3 months is 36.711M and the stock's 52-week low/high is $3.225/$23.5125.

Ambrx Biopharma (AMAM)

QualityStocks, MarketClub Analysis, MarketBeat and Schaeffer's reported earlier on Ambrx Biopharma (AMAM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ambrx Biopharma Inc. (NYSE: AMAM) is a clinical-stage biologics firm that is focused on the discovery and development of engineered precision biologics through the use of its proprietary expanded genetic code technology platform.

The firm has its headquarters in La Jolla, California and was incorporated in 2003. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers in the United States.

The company is party to collaborations with a number of pharmaceutical companies, including Elanco Animal Health, Astellas Pharma Inc., and the Bristol Myers Squibb Company.

The enterprise’s product portfolio is comprised of an anti-HER2 ADC (antibody-drug conjugate) dubbed ARX788, which is in a phase II/III clinical trial testing its efficacy in treating gastric cancer and HER2-positive metastatic breast cancer as well as undergoing various clinical trials evaluating its effectiveness in treating gastric/gastroesophageal junction cancer, breast cancer and other solid tumors. It is also developing an anti-CD70 ADC known as ARX305, which is under study for the treatment of renal cell carcinoma and other cancers; and an anti-PSMA ADC dubbed ARX517, for the treatment of prostate cancer and other solid tumors. In addition to this, the enterprise is developing a fab-small molecule bispecific known as ARX822, which is in preclinical development for various oncological indications; and an immune-oncology IL-2 pathway agonist dubbed ARX102.

The company’s ARX788 formulation presented positive safety and effectiveness data in its clinical trial for the treatment of breast cancer. The company is focused on advancing its clinical candidates to create better treatment outcomes for patients, and growing to create value for its stakeholders.

Ambrx Biopharma (AMAM), closed Thursday's trading session at $6.53, up 43.2018%, on 36,940,976 volume. The average volume for the last 3 months is 16.257M and the stock's 52-week low/high is $0.38/$7.39.

Indoor Harvest  Corp. (INQD)

QualityStocks, SmallCapVoice, InvestorPlace, MarketBeat, Cannabis Financial Network News, CFN Media Group, Stock Shock and Awe, Penny Stock General, OTPicks, Orbit Stocks, Fast Money Alerts, PennyPickAlerts, MassiveStockProfits and MarketClub Analysis reported earlier on Indoor Harvest  Corp. (INQD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Indoor Harvest  Corp. is a developer of personalized cannabis medicines. In addition, the Company is a provider of advanced cultivation technology, methods, and processes. Indoor Harvest provides the cannabis industry production platforms for Building Integrated Agriculture (BIA) production. Established in 2011, the Company has its corporate headquarters in Houston, Texas. It is now moving its base of operations and focus to the Boston, Massachusetts area to leverage what it believes to be an attractive environment for cannabis companies since Massachusetts has legalized medicinal and recreational cannabis.

Indoor Harvest has transitioned into a producer of cannabis for research and pharmaceutical development. The Company’s patent pending aeroponic methods allow for the production of chemically consistent, contaminate free cannabis, economically at scale.

Indoor Harvest’s Management is working to deploy its integrated aeroponic technology platform, on its own and with partners in the Boston area, to demonstrate and highlight the Company’s belief in the technology’s ability to considerably decrease operating costs while boosting yield and quality.

Indoor Harvest  Corp. (INQD), closed Thursday's trading session at $0.0093, up 39.8496%, on 16,257,279 volume. The average volume for the last 3 months is 155.034M and the stock's 52-week low/high is $0.0046/$0.015.

Vascular Biogenics (VBLT)

StockMarketWatch, INO.com Market Report, MarketBeat, BUYINS.NET, QualityStocks, StreetInsider, Trades Of The Day, Schaeffer's, MarketClub Analysis, TraderPower, Marketbeat.com, StockOodles, Streetwise Reports, Trading Concepts, The Best Newsletters, AllPennyStocks, MarketArmor.com, Market FN, Jason Bond, InvestorGuide, Greenbackers, Daily Trade Alert, TradersPro and Barchart reported earlier on Vascular Biogenics (VBLT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vascular Biogenics Ltd. (NASDAQ: VBLT) is a clinical biopharmaceutical firm which is engaged in discovering, developing and commercializing treatments for immune-inflammatory ailments and cancer.

The company has its headquarters in Modiin-Maccabim-Reut, Israel and was incorporated in 2000, on January 27 by Jacob George and Dror Harats. The enterprise’s product brands include Vascular Therapeutics, Vascular Biogenics, Vbl, Vascular Targeting Systems and VTS.

Prior to its name change in January 2003, the firm was known as Medicard Ltd. It operates as part of the medical and diagnostic laboratories industry.

The company’s product candidates include a gene based biologic dubbed VB-111, which was developed for solid tumor indications for recurrent glioblastoma and is currently undergoing a phase 2 clinical trial for treating colorectal cancer and recurrent glioblastoma, as well as undergoing another phase 3 clinical trial for recurrent platinum-resistant ovarian cancer. The candidate recently concluded a phase 2 clinical trial which tested its effectiveness in treating thyroid cancer. The company also develops an anti-angiogenic drug known as VB-511 for oncological indications; VB-611 for solid tumors; VB-601 for inflammatory indications; VB-411 and VB-211, which are pro-angiogenic compounds indicated for treating peripheral vascular ailments.

The enterprise announced recently that its phase 3 VB-111 study for recurrent ovarian cancer had no safety issues, with a committee recommending the trial’s continuation. The candidate may soon obtain approval from the FDA if the trial’s results are successful, which would be beneficial to both the patients that suffer from this debilitating ailment and the company.

Vascular Biogenics (VBLT), closed Thursday's trading session at $0.1683, up 29.661%, on 155,034,420 volume. The average volume for the last 3 months is 675,019 and the stock's 52-week low/high is $0.1009/$2.20.

Elevation Oncology (ELEV)

Actual Gains, QualityStocks, PennyStockRumors.net, OTCPicks, Buzz Stocks, FeedBlitz, HEROSTOCKS, Liquid Pennies, MarketBeat, PennyTrader Publisher, WhisperFromWallStreet, SmallCapStockPlays, Stock Brain, Stock Exploder, Stockhunter.us, The Night Owl, VIP STOCK ALERTS and Otcstockexchange reported earlier on Elevation Oncology (ELEV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elevation Oncology Inc. (NASDAQ: ELEV) is a clinical-stage biopharmaceutical firm that is engaged in the development of therapeutics for treating cancer in genomically-defined patient populations.

The firm has its headquarters in New York and was incorporated in 2019 by Shawn M. Leland. It serves consumers in the United States.

The company’s objective is to introduce new targeted therapies for patients with cancer as well as illuminate what the company is doing to create a future where every patient can receive care built around targeting their unique tumor drivers and understanding. This will be done by having every tumor’s unique genomic test result matched with a purpose-built precision medicine that will allow the use of individualized treatment plans for patients.

The enterprise’s formulations identify and target inhibition of tumor-specific drive alterations. Its product portfolio comprises of an anti-HER3 monoclonal antibody dubbed seribantumab, which is undergoing a phase 2 Crestone trial evaluating its effectiveness in treating advanced solid tumors that harbor neuregulin-1 fusions (NRG1 fusions).The NRG1 gene fusions are rare genomic alterations which combine NRG1 with other partner proteins to create a chimeric NRG1 fusion protein. These fusions have been identified in a variety of solid tumors, including cholangio carcinomas, neuroendocrine, colorectal, ovarian, breast, gallbladder, pancreatic, lung and sarcomas.

The firm is focused on making progress on its mission to bring purpose-built medicines to patients suffering from genomically defined cancers. The success of their formulations will not only address unmet needs in patients but also bring in more investments into the firm.

Elevation Oncology (ELEV), closed Thursday's trading session at $1.26, up 27.2727%, on 675,019 volume. The average volume for the last 3 months is 281,045 and the stock's 52-week low/high is $0.7229/$4.6099.

NGM Biopharmaceuticals (NGM)

MarketBeat, StreetInsider, Daily Trade Alert, BUYINS.NET, Trades Of The Day, InsiderTrades, AllPennyStocks, TradersPro, Streetwise Reports, StockMarketWatch, Schaeffer's and InvestorPlace reported earlier on NGM Biopharmaceuticals (NGM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NGM Biopharmaceuticals Inc. (NASDAQ: NGM) (FRA: 01K) is a biopharmaceutical firm focused on discovering and developing new therapies for the treatment of retinal illnesses, liver and metabolic diseases, and cancer.

The firm has its headquarters in South San Francisco, California and was incorporated in 2007, on December 20th by Jin-Long Chen. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves patients in the United States.

The company is party to a collaboration agreement with Merck & Co. Inc, focused on the development of new medicines for unmet patient needs in retinal and CVM diseases, including heart failure. It is also party to research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.

The enterprise’s product pipeline is comprised of an engineered analog of human hormone fibroblast growth factor 19 dubbed Aldafermin, which is in Phase IIb trials for the treatment of non-alcoholic steatohepatitis (NASH); and an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klothodubbed MK-3655, which is in Phase IIb clinical trials for use in the treatment of NASH and type 2 diabetes. Its products under development include NGM621, an immunoglobulin 1 monoclonal antibody in Phase 2 trials for the treatment of geographic atrophy; NGM831 and NGM438 for the treatment of advanced solid tumors; and an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody dubbed NGM707, which is in Phase I/II clinical trials for the treatment of advanced solid tumors.

The firm recently outlined its corporate strategy, with its CEO noting that they remained focused on clinical development efforts of its oncology programs. The success and approval of its formulations will benefit patients with various indications while also increasing investments into the firm.

NGM Biopharmaceuticals (NGM), closed Thursday's trading session at $4.65, off by 1.4831%, on 291,426 volume. The average volume for the last 3 months is 174,071 and the stock's 52-week low/high is $2.92/$18.25.

Gracell Biotechnologies (GRCL)

MarketBeat, Trades Of The Day and MarketClub Analysis reported earlier on Gracell Biotechnologies (GRCL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gracell Biotechnologies Inc. (NASDAQ: GRCL) is a clinical-stage biopharmaceutical firm focused on the discovery and development of cell therapies for treating cancer.

The firm has its headquarters in Suzhou, China and was incorporated in 2017 by William Wei Cao. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the People’s Republic of China.

The enterprise’s product pipeline is comprised of a FasTCAR-enabled CD19-directed autologous CAR-T product candidate dubbed GCO19F, which is in Phase I trials for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in the preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). It also develops GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T formulation in Phase I clinical trials for the treatment of multiple myeloma; and a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T candidate dubbed GC502, which is in Phase I trial for the treatment of B-cell malignancies. This is in addition to developing GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T candidate in Phase I trials for the treatment of adult T cell acute lymphoblastic leukemia. The enterprise also has a portfolio of earlier stage product candidates targeting a range of cancer indications, including breast cancer, ovarian cancer, T cell lymphoblastic leukemia and peripheral T cell lymphoma.

The company’s GC012F candidate recently received clearance for its Investigational New Drug application. The approval and commercialization of this candidate will benefit patients with relapsed/refractory multiple myeloma greatly while also bringing in additional revenues and investments into the company.

Gracell Biotechnologies (GRCL), closed Thursday's trading session at $2.05, off by 2.381%, on 174,731 volume. The average volume for the last 3 months is 337,898 and the stock's 52-week low/high is $1.68/$5.6905.

Consolidated Communications (CNSL)

Kiplinger Today, StreetInsider, MarketBeat, The Online Investor, Marketbeat.com, Zacks, InvestorPlace, The Street, MarketClub Analysis, Top Pros' Top Picks, TheStockAdvisors, Daily Trade Alert, Greenbackers, SmarTrend Newsletters, StreetAuthority Daily, TradersPro, Trades Of The Day, SmallCap Network, FreeRealTime, BUYINS.NET, Dividend Opportunities, Investors Alley, Money Morning, Barchart, Short Term Wealth, StockMarketWatch, Stocks To Watch, Street Insider and Schaeffer's reported earlier on Consolidated Communications (CNSL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Consolidated Communications Holdings Inc. (NASDAQ: CNSL) (FRA: C8C) offers broadband and business communication solutions for consumer, commercial, and carrier channels in the United States.

The firm has its headquarters in Mattoon, Illinois and was incorporated in 1894, on August 10th by Iverson A. Lumpkin. It operates as part of the telecom services industry, under the communication services sector. The firm serves consumers in the United States.

The enterprise provides commercial data connectivity services in various markets, including Ethernet services, private line data services, software defined wide area network, and multi-protocol label switching services; high-speed broadband internet access and voice over Internet Protocol (VoIP) phone services; cloud-based services; networking services; data center and disaster recovery solutions; and wholesale services to national and regional interexchange, and wireless carriers comprising cellular backhaul and other fiber transport solutions. It also offers voice services, such as local phone and long-distance services; as well as related hardware and maintenance support, video, and other miscellaneous services. This is in addition to selling business equipment and offering video services, which comprise high-definition television, digital video recorders (DVR) and/or a whole home DVR; and on-demand streaming TV services that provide endless entertainment options. Further, the enterprise offers network access services that include network special access, interstate and intrastate switched access, and end user access; as well as telephone directory publishing, video advertising, billing and support, and other miscellaneous services.

The company, which was recently named the U.S. Best-in-Class Employer by Gallagher, remains focused on providing an industry-leading customer experience. This will bolster the company’s overall growth.

Consolidated Communications (CNSL), closed Thursday's trading session at $4.03, off by 4.0476%, on 346,641 volume. The average volume for the last 3 months is 2,841 and the stock's 52-week low/high is $3.50/$8.49.

Reading International (RDI)

MarketBeat, OnTheMar, InvestorPlace, StreetInsider, The Street, Marketbeat.com, Early Bird, TradersPro, SmarTrend Newsletters, David Cohen and Barchart reported earlier on Reading International (RDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Reading International Inc. (NASDAQ: RDI) (FRA: 46B) is an entertainment and real estate firm focused on owning, developing and operating entertainment and real property assets.

The firm has its headquarters in New York and was incorporated in 1999 by James J. Cotter Sr. It operates as part of the entertainment industry, under the communication services sector. The firm serves consumers in the United States, New Zealand and Australia.

The enterprise operates through the Cinema exhibition and Real estate segments. The Cinema Exhibition segment operates multiplex cinemas. This segment manages its cinema exhibition businesses under the Reading Cinemas, Angelika Film Centers, Consolidated Theaters, City Cinemas, Event Cinemas and Rialto Cinemas brands. On the other hand, the Real Estate segment is involved in developing, owning, renting or licensing retail, commercial and live theater assets. As of December 2020, the enterprise had interests in 63 cinemas consisting of roughly 515 screens; fee interest in 44 Union Square property; fee interests in two live theaters; and fee interest in one cinema in Manhattan. It also has fee interest in entertainment-themed centers; fee interests in two cinemas in Australia and three cinemas in New Zealand; fee interest in 2 office buildings; and fee ownership of approximately 8.9 million square feet of developed and undeveloped real estate assets.

The company, whose latest financial results show increases in its revenues, remains focused on capitalizing on pent up industry demand, leveraging its strategic adaptability and delivering value for its shareholders.

Reading International (RDI), closed Thursday's trading session at $3.55, up 0.852273%, on 3,003 volume. The average volume for the last 3 months is 1.028M and the stock's 52-week low/high is $2.65/$4.88.

Veru Inc. (VERU)

MarketClub Analysis, Schaeffer's, MarketBeat, TradersPro, StockMarketWatch, The Wealth Report, Kiplinger Today, BUYINS.NET, Trades Of The Day, The Street, StreetInsider, InvestorPlace, Daily Trade Alert, QualityStocks, Trading Concepts, Zacks, Investopedia, INO Market Report and Money Morning reported earlier on Veru Inc. (VERU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Veru Inc. (NASDAQ: VERU) (FRA: FMW) is a biopharmaceutical firm focused on the development of drugs for the management of breast and prostate cancers as well as COVID-19.

The firm has its headquarters in Miami, Florida and was incorporated in 1996 by O.B. Parrish and William R. Gargiulo Jr. Prior to its name change in July 2017, the firm was known as The Female Health Company. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe, with offices in Kuala Lumpur, Malaysia and London, United Kingdom.

The company’s commercial products include Entadfi, a capsule for the treatment of urinary tract symptoms; and FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections. Its candidates under development include Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; an oral selective androgen receptor agonist dubbed Enobosarm, which is in phase III trials for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Enobosarm + abemaciclib combination therapy, which is in phase III trials for the treatment of AR+ ER+ HER2- metastatic breast cancer. It also develops a GnRH antagonist peptide injection known as VERU-100, which is in Phase II trials for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase 2b trials for the treatment of hot flashes; and Sabizabulin, which is in Phase 3 trials for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer.

The enterprise recently announced its latest financial results, with its CEO noting that they were focused on advancing its product pipeline and increasing revenues from its sexual health program. This will help create value for its shareholders.

Veru Inc. (VERU), closed Thursday's trading session at $4.42, off by 1.3393%, on 1,027,752 volume. The average volume for the last 3 months is 773,143 and the stock's 52-week low/high is $3.88/$24.55.

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, StreetInsider, Dynamic Wealth Report, Uncommon Wisdom, Marketbeat.com, MarketClub Analysis, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, PennyOmega, BestOtc, Schaeffer's, StockHotTips, TraderPower, PennyToBuck, StockOodles, Street Insider, The Street and TopPennyStockMovers reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In just a few short years, psychedelics have presented themselves as a potential alternative to pharmaceutical mental health therapies. Research into hallucinogenic drugs has revealed that they are capable of alleviating the symptoms of mental disorders, such as treatment-resistant depression, anxiety and PTSD, when paired with psychotherapy.

But while countries such as the United States and Australia have taken great strides towards increasing psychedelic research and incorporating psychedelics into existing mental health treatment frameworks, the European Union is still trailing behind. A cross-party group of legislators is now calling on the EU to step up its efforts and act fast on psychedelic research.

In a recent letter to Emer Cooke, executive director of the European Medicines Agency, the group of lawmakers urged parliament to turn its attention to psychedelic research and consider legislative changes that would make it easier for researchers to study hallucinogenic drugs and develop viable mental health treatments.

Although we are currently in the midst of a psychedelic research renaissance, most of the legislative efforts geared at making this research and resultant psychedelic treatments more accessible have been outside the EU. Thus far, studies have found that psychedelics such as MDMA, psilocybin and ketamine have the potential to treat conditions such as post-traumatic stress disorder, treatment-resistant depression, anxiety, eating disorders and alcohol-use disorder.

However, Europe has barely made any regulatory changes to make it easier for researchers to study psychedelics or increase patient access to psychedelic-assisted therapies.

Australia became the first country in the world to allow psychiatrists to prescribe psilocybin and MDMA-based treatments to alleviate treatment-resistant depression and PTSD earlier this year.

In the U.S., Oregon passed a bill to legalize psilocybin last year, and more states are set to vote on psychedelic measures this year as part of a wave of psychedelic reform that has swept through the country.

The recent letter to the European Parliament highlighted the lack of similar progress in the EU and noted that this had disadvantaged millions of Europeans who are suffering from substance-use disorders and mental-health conditions that could be treated by psychedelic-assisted therapies.

The legislators who signed the letter want the European Medicines Agency to be active in promoting psychedelic research and the development of psychedelic-based mental health therapies. The legislators also listed a variety of questions and challenges that have to be addressed before the EU can fully adopt psychedelic treatments, such as understanding their risks compared to other pharmaceutical alternatives.

They suggested that the medicines regulator liaise closely with the European Monitoring Center for Drugs and Drug Addiction, plan workshops with relevant parties and create a report.

The lawmakers have reason to be concerned, especially in the light of the progress being made by teams at different North American-based companies such as atai Life Sciences N.V. (NASDAQ: ATAI) focused on developing psychedelics medicines.

atai Life Sciences N.V. (ATAI), closed Thursday's trading session at $1.7, off by 2.2989%, on 774,269 volume. The average volume for the last 3 months is 12.367M and the stock's 52-week low/high is $1.45/$5.99.

Atlis Motor Vehicles Inc. (AMV)

Money Wealth Matters, QualityStocks, The Stock Dork, MarketBeat and 247 Market News reported earlier on Atlis Motor Vehicles Inc. (AMV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Electric cars are surging in popularity as more models are being introduced into the market each year. Although electric cars have several advantages over fuel-powered cars, the two types of vehicles require distinct procedures when it comes to repair and maintenance.

Electric cars use motors and rechargeable batteries to power the wheels, unlike conventional cars, which utilize combustion engines to do so. This implies that electric cars can only be handled by qualified auto dealers and not just any auto shop since specialized equipment as well as particular training are needed when it comes to repairing and maintaining them.

However, this is expected to turn around in the near future, as car-repair companies have started to adjust to the reality that electric vehicles are increasing rapidly each year and are now spending money on training specialists and tools to satisfy their clients’ needs. According to the most recent AutoTechIQ research, the demand for this training as well as the certified courses is increasing.

Vehicle batteries present a significant challenge when it comes to EV repairs and maintenance. Battery replacement costs are among the highest of any electric vehicle, despite batteries being one of the most essential parts in a vehicle. However, technological advances are emerging that enable battery repairs or prolong the lifespan of a battery. Freewire, for instance, is creating a mobile service repair for batteries that enables fixing batteries on the spot, offsetting the requirement for pricey replacements.

The future will also see the adoption of remote diagnostics to fix electric vehicles. These days, many electric vehicles have sensors installed that can identify problems associated with the vehicle and report the same to the vehicle manufacturer. This, in turn, can aid in the early detection of issues and, in some circumstances, even enable remote fixes.

In general, the future of fixing electric cars is promising since the advanced technology that will make fixing electric vehicles simpler and more economical is being invented. As such, consumers can anticipate an easier, more efficient repair procedure in the upcoming years.

In short, electric vehicles have the potential to revolutionize our approach to vehicle repair and maintenance. Auto businesses are investing in equipment as well as training experts so as to satisfy clients’ needs. At the same time, advanced technologies such as remote diagnostics and mobile battery repair services are also being developed. To ensure that your EV is maintained properly and serviced, it’s crucial to choose a repair facility that focuses on electric vehicles.

This precaution is especially vital if you own an electric work truck from any of the existing manufacturers such as Atlis Motor Vehicles Inc. (NASDAQ: AMV), since these are subjected to exerting conditions and have to be at their peak in order to perform well.

Atlis Motor Vehicles Inc. (AMV), closed Thursday's trading session at $1.02, up 10.8696%, on 12,366,783 volume. The average volume for the last 3 months is 1.305M and the stock's 52-week low/high is $0.88/$243.99.

The QualityStocks Company Corner

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

The uranium market performed admirably in January due to increaseddemand for nuclear energy amid global energy shortages and soaring energy prices. Sprott recently released a report stating that the uranium market performed well in January, as the spot price of U308 uranium increased to $50.75 per poundfrom $48.31 last month and uranium mining equities went up by14.65%. Spot prices for U308 uranium have gone up by about 104.23% since 2019 and 14.74% in 2022, signifying themarket’s continued upward trajectory over the last few years.Uranium mining equities, on the other hand, bounced back last monthafter experiencing an 11.42% decline over the course of last year.Even though the demand for uranium and nuclear energy soared in2022 and was bolstered by support from global governments, pricesfor uranium mining equities lagged due to the systemic risk presented to overall markets. But as investor sentiment shifted inJanuary and headwinds for equity markets began to diminish, uraniummining equities experienced a significant surge in value. Overall,the jump in uranium mining equities last month represents a hugegain of 213.63% from Dec. 31, 2019, to Jan. 31, 2023. When uraniumstarts being seen as a hedge against inflation, stocks ofextractors such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) could be in the spotlight as investors look to shore up theirpositions.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Thursday's trading session at $6.62, up 1.8462%, on 1,305,387 volume. The average volume for the last 3 months is 15,528 and the stock's 52-week low/high is $4.69/$11.00.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria’s 2022 R&D efforts saw high levels of success,establishing the company as one of the world’s leaders in theinvestigation of CBD for controlling human blood pressure and,separately, demonstrating performance enhancements compared to oneof the world’s leading anti-seizure medications

During Q1 2023, Lexaria expects to provide additional results fromits hypertension study HYPER-H21-4; complete dosing in thecompany’s animal dementia and diabetes studies; complete dosing inthe human nicotine study NIC-H21-1; and submit and publishadditional results in research journals

Lexaria’s DehydraTECH technology currently has 28 granted patents,with many more pending patents in countries worldwide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using itspatented DehydraTECH(TM) technology to improve the way activepharmaceutical ingredients (“APIs”) enter the bloodstream bypromoting healthier oral ingestion methods and increasing theeffectiveness of fat-soluble active molecules. In a letter toshareholders last month, Lexaria CEO Chris Bunka provided athorough strategic update and insight into the company’s planmoving forward.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $3.0599, up 0.32459%, on 15,547 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $11.00/$.

Recent News

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) has obtained conditional approval to list its common shares on theToronto Stock Exchange (“TSX”). According to the announcement,Eloro shares will trade under the trading symbol: ELO. Theannouncement also noted that the listing is subject to EloroResources fulfilling certain requirements of the TSX; those termswere outlined in a conditional approval letter that was dated Feb.22, 2023. “This is a significant milestone for Eloro and itsshareholders,” said Eloro Resources CEO Thomas Larsen in the pressrelease. “The TSX is one of the world's pre-eminent exchanges formineral resource companies. A TSX listing will increase ourvisibility and profile in the capital markets and in the miningindustry. Listing on the TSX will also offer benefits toshareholders such as enhanced market access for Canadian andinternational investors, increased access to capital and improvedliquidity, as the company advances its flagship Iska Iska projectin southern Bolivian.”

To view the full press release, visit https://ibn.fm/scIU2

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.

Projects

Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Thursday's trading session at $2.36, up 0.425532%, on 9,687 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.09/$4.46.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

EverGen Infrastructure CEO, Chase Edgelow recently joined a webinarhosted by Adelaide Capital to provide investors and stakeholderswith an update on the company’s operations

Edgelow elaborated on the company’s portfolio, including its 4existing revenue generating assets, 2 projects currently underconstruction as well as its Ontario-based Greenfield project,Project Radius

By 2Q 2023, EverGen anticipated that the completion of its RNGprojects would drive gross generating capacity to 240,000 GJ/annum,whilst growing EBITDA by $5-7m per year

In the longer term, successful execution on EverGen’s Ontario-basedGreenfield project could see the company expand its RNG productionby as much as 1.7 million GJ/year

British-Columbia based natural gas operator, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), has long held aspirations of transforming into Canada’s leadingRNG infrastructure platform, in the process securing stronglong-term contracted cash flows. The company today operates 4revenue generating assets across 3 key regions in Canada, alongside2 RNG projects currently under construction as well as oneOntario-based project in development. EverGen Infrastructure CorpCEO, Chase Edgelow recently participated in a webinar hosted byAdelaide Capital to provide investors with an update on thecompany’s ongoing operations as well as their prospects goingforward (https://ibn.fm/XPI4q).

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Thursday's trading session at $2.37, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $1.365/$4.00.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

All American citizens who suffer from the burden associated with federal cannabis-related convictions on their prior record were meant to be granted unconditional pardons, per the president’s directive in October. According to the president, thousands of Americans have existingfederal records for cannabis use and risk being denied work,residence or educational prospects. Never in history has apresident-elect publicly acknowledged the shortcomings of America’salmost century-long experiment with marijuana restriction, ameasure that most states have already abandoned. Currently, abouttwo-thirds of citizens believe it has to be done away with.Additionally, no president has ever shown commitment to using theoffice’s pardoning authority to help so many people who had beenharmed by that failed program. For jurisdictions where legalmarijuana markets exist, economies are thriving and the trickledown effects are also boosting entities such as Advanced Container Technologies Inc. (OTC: ACTX) that focus on meeting the needs of cannabis companies andindividual growers.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Thursday's trading session at $0.44, even for the day, on 5 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.25.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Immunotherapy is one of the newest cancer treatment options that has made itpossible for physicians to target and treat cancer moreeffectively. This treatment works by helping a patient’s immune system to kill cancer cells rather than using pharmaceuticals or radiation therapy to directlyfight the cancer cells.Immunotherapy typically has fewer side effects compared to other cancer treatment options, and it can be used oncancers such as skin cancer, which don’t respond well to othertreatments, including chemotherapy, and it may prevent cancer fromreturning by boosting the immune system’s ability to fight cancer cells.However, immunotherapies aren’t universal cancer treatments becausethey aren’t effective with every type of cancer and every cancerpatient. As such, scientists are still carrying out research to identify why immunotherapy isn’t always effective with every cancer patient and type of cancer. As more entities suchas CNS Pharmaceuticals Inc. (NASDAQ: CNSP) devote more resources to studying different cancers and how noveltreatments can be developed leveraging this new information,patients could soon have superior treatments to opt for and have abetter quality of life despite their cancer diagnosis.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $1.59, off by 2.5735%, on 23,767 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.55/$16.50.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelicsto Therapeutics(TM), has announced a strategic plan designed tostreamline efforts, maximize operating efficiency and focus oncritical clinical trials, including near-term, mid-term andlong-term milestones. A part of that plan was the release of anestimated 15% of Cybin’s workforce, including those in roles thatwere identified as not a clinical priority or not directly involvedwith any clinical trial initiatives. This move alone is expected togenerate cost savings by reducing operating expenses. Theannouncement noted that with the anticipated cost savings from theoverall streamlining efforts combined with Cybin’s ongoing andpreviously announced $35 million At-the-Market (“ATM”) equityprogram, the company will be better positioned for both near-termand long-term success. The announcement observed that Cybin hasevolved from discovery-stage to clinical-stage operations,necessitating a clinical alignment designed to leverageintellectual property generated from its discovery efforts forclinical development and focus on clinical execution. “The companyhas made the prudent decision to evaluate every role within itsworkforce, including whether certain tasks could be performed moreefficiently while ensuring that the company’s core clinicalactivities continue to be robustly supported and resourced,” saidCybin CEO Doug Drysdale in the press release. “We appreciate thesignificant contributions of our employees and the hard work theyperformed for the company and understand the impact that thisdifficult decision has on them. We are committed to maintaining alean organization and will continue to make clinical trialexecution in support of our proprietary molecules our toppriority.” To view the full press release, visit https://ibn.fm/RIvCs

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Thursday's trading session at $0.4754, off by 6.766%, on 1,526,049 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2649/$1.14.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

In January, Senate Majority Leader Chuck Schumer (D-NY) convened asecond meeting to discuss cannabis legislation for the 118thCongress. This time, he invited a group of Republican senators to strategize the next steps for drafting a bill that could pass.The first meet-up with Democratic colleagues occurred at the beginning of February. In the recent meeting, theGOP leaders present included Senators Dan Sullivan (R-AK), RandPaul (R-KY), and Steve Daines (R-MT). The aim of these meetings isto establish a mechanism through which legislators can reach abipartisan agreement on marijuana reform bill goals in the currentRepublican-controlled Congress. Cannabis supporters are hoping forcooperation on the SAFE Plus legislation, which the senate majorityleader worked to promote in the last days of the previous session.The SAFE Plus bill was anticipated to include provisions formarijuana banking and expungements alongside other potential minorreforms. Chances are high that marijuana industry operators suchas India Globalization Capital Inc. (NYSE American: IGC) will closely follow any developments on Capitol Hill pertaining tomarijuana policy reform.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Thursday's trading session at $0.386, off by 1.0256%, on 64,137 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$1.16.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Export services under NAFTA, mainly covering transportation,travel, business, and financial services, increased from $14.7billion in 1999 to $30.4 billion in 2021

With the transition from NAFTA to USMCA, trade in goods andservices is set to see a spike from 2022 going forward, and Fr8Techexpects to capitalize on this

Freight Technologies Inc., with its superior freight platform forNorth American cross-border shipping, yielded a 45% YOY revenuegrowth for Q2 2022, which it looks to surpass in the subsequentquarters of the current financial year

With trucks moving about 70% of North American surface trade byvalue, trucking companies, Fr8Tech included, are set to be thebiggest beneficiaries with the USMCA, enjoying benefits such asreduced administrative burdens and faster shipping times

The USMCA’s objective is to support a mutually beneficial tradethat seeks to achieve more accessible markets, fairer trade, andeconomic growth in North America. Fr8Tech looks to capitalize onopportunities that present themselves to not only createshareholder value but also grow its brand equity and realize itsshort-term and long-term objectives

According to the United States Census Bureau, the export ofservices under the North American Free Trade Agreement (“NAFTA”),mainly covering transportation, travel, business, and financialservices, increased from $14.7 billion in 1999 to $30.4 billion in2021. The same applies to the trade of services between the U.S.and Canada. With the transition from NAFTA to the UnitedStates-Mexico-Canada Agreement (“USMCA”), it is projected thattrade in goods and services in the region will not be altered. Thestudy projects that operations in this sector will soar as tradeamong the three countries grows (https://ibn.fm/2BEFI).Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an enterprise developing solutions to optimize andautomate the supply chain process and offering a platform for B2Bcross-border shipping in the NAFTA (now USCMA) region looks tocapitalize not just on the smooth transition, but also therelatively unaltered trade in goods and services to grow its marketshare and achieve its revenue objectives. This level of focus hasallowed the company to achieve a 45% year-over-year (“YOY”) revenuegrowth for the second quarter of the 2022 financial year, which Itlooks to surpass in the subsequent quarters of the currentfinancial year (https://ibn.fm/IDih3).

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.

Fr8University

Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Thursday's trading session at $0.275, off by 3.8129%, on 1,304,325 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1799/$3.60.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

SideChannel recently released its financial results for Q1 2023,recognizing $1,546,000 in revenue, a 48% year-over-year increase

The company also ended the fiscal quarter with $2,553,000 in cash,having spent about $480,000 to offset R&D and marketingexpenses

SideChannel is in the business of providing cybersecurityleadership and program development through its team of virtualChief Information Security Officers (“vCISOs”)

The company has also developed Enclave, a micro-segmentationsoftware that recently received FIPS 140 certification, opening thedoor for SideChannel to pursue federal and state contracts andfurther increase cybersecurity revenue

SideChannel (OTCQB: SDCH), a company focused on delivering cybersecurity programs as aservice and complimentary solutions to small and middle-marketcompanies that have long been priced out of cybersecuritysolutions, recently announced its financial results for the quarterended December 31, 2022 (“Q1 2023”). The company recognized a 48%year-over-year revenue growth from $1,048,000 in Q1 2022 to$1,546,000 in the just-ended quarter (https://ibn.fm/ZQIlD). Furthermore, the Q1 2023 revenue represented a 26%quarter-over-quarter growth from Q4 2022 figures.SideChannel (OTCQB: SDCH) has named a new board chair. The company announced that former IBMexecutive Deborah MacConnel will be serving in the leadershipposition, replacing Tom Wilkinson. MacConnel was elected to therole during the company’s annual meeting of stockholders andinvestor day event, held on Feb. 15, 2023. The company alsoannounced two new board members: Anthony Ambrose, president and CEOof Data I/O Corp., and Kevin Powers, founder, director andprofessor of cybersecurity, data privacy and national securitygraduate programs at Boston College. During the meeting,stockholders also granted the board authority to combineoutstanding shares of SideChannel’s common stock into a lessernumber of outstanding shares; the exact ratio will be determined bythe board of directors within a range of 1-for-2 to a maximum of1-for-100. “SideChannel is doing something special,” said newlyelected SideChannel board chair Deborah MacConnel in the pressrelease. “They are focused on solving a significant challenge formid-market companies, and I look forward to working with the othermembers of the board to support and monitor SideChannel’sprogress.” To view the full article, visit https://ibn.fm/Ce3Ms

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.

 

Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.

Enclave

Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Thursday's trading session at $0.08, off by 30.4348%, on 388,975 volume. The average volume for the last 3 months is 388,975 and the stock's 52-week low/high is $0.0675/$0.18.

Recent News

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

Sugarmade (OTC: SGMD), a product and branding marketing company investing in operationsand technologies with disruptive potential, today announced itsentry into a binding letter of intent (“LOI”) to acquire the realestate assets and businesses of Treasure Mountain Holdings, LLC andVictorville Treasure Holdings, LLC. Management believes that thefull resolution of this strategic process will result in two newdynamic growth-oriented business entities. These include a legacyOTC company engaged in the legal cannabis marketplace and a newNASDAQ-listed company involved in hospitality, entertainment andmultimedia flex-makerspace operations. “This deal will carrymultiple synergistic elements and tremendous value creation,” saidJimmy Chan, CEO of Sugarmade. “TheMediaBox is an idea whose timehas come, and this is the perfect vehicle to launch it. We areembarking on a new chapter that stands to deliver significant valueto our shareholders as we expand our asset base and revenue streamsand diversify our model with an eye toward a major exchangelisting.”

To view the full press release, visit https://ibn.fm/63iai

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

  • NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
  • BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.

Management

Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Thursday's trading session at $0.0001, off by 50%, on 132,997,544 volume. The average volume for the last 3 months is 132.998M and the stock's 52-week low/high is $0.0001/$0.0009.

Recent News

Laredo Oil Inc. (OTC: LRDC)

The QualityStocks Daily Newsletter would like to spotlight Laredo Oil Inc. (LRDC).

Laredo Oil Inc. (OTC: LRDC) is a publicly traded oil and gas exploration and production (E&P) company engaging in the acquisition and development of both undervalued quality conventional oil and gas properties and select mature oil fields that are suitable for the company’s proprietary Enhanced Oil Recovery (EOR) methods.

Laredo Oil is headquartered in Austin, Texas.

Conventional Acreage

Laredo Oil’s primary focus is on acquiring, developing, and operating undervalued conventional oil and gas properties.

The company leased 23,739 mineral acres in the Western Williston Basin of Montana, at favorable prices during the most recent down cycle and continues to take leases in the area. Before year end, it expects to drill the first development well at one of the first of 10 potential locations it has identified. If that well yields the anticipated results, the company plans to begin drilling additional wells there as soon as practical thereafter. The company believes the leased acreage has the potential to yield at least five years of development opportunities.

The company intends to pursue aggressively the acquisition of quality assets that major, mid-major, and large independent oil and gas companies continue to divest themselves of at a discount in response to ESG (Environmental, Social and Governmental) & sustainability initiatives and other pressures imposed upon them by their activist boards of directors. The company will focus on value, growth potential and free cash flow while complying with common sense ESG policies, often having a lower environmental impact than its competitors through its EOR methods.

EOR

In addition to pursuing conventional acreage and properties, Laredo Oil plans to acquire additional select mature oil fields where it believes that it can profitably use its proprietary Underground Gravity Drainage™ (UGD) model to recover stranded oil reserves (reserves previously considered to be economically incapable of recovery). The UGD method is applicable to mature oil fields that have very specific geological and reservoir characteristics.

Laredo Oil has done extensive research and field level application over the last 10 years and has identified specific oil fields within the United States that it believes are qualified for the UGD recovery method. The company believes the costs of implementing the UGD method are significantly lower than those of other commonly used EOR methods. Laredo Oil believes that it can materially increase the field oil production rate from prior periods and, in some cases, recover amounts of oil equal to or greater than amounts previously recovered from the mature fields selected.

Market Outlook

The company expects U.S. oil prices to climb in the near term as energy demand intensifies with the economy continuing to recover from the COVID-19 slowdown. Also causing upward price pressure is global supply chain dysfunction that slows or prevents shipments, including energy components, from reaching destinations. Domestic oil production is also constrained by years of reduced investment in fossil fuel producers due to green energy mandates. Accordingly, the company believes that the short-term outlook for oil is favorable. Many industries have yet to reach their pre-COVID production levels, which the company believes points to a continuing near-term upward trend in energy demand.

Management Team

Mark See has been the Chief Executive Officer and Chairman of the Board of Directors of the company since October 16, 2009. He has over 30 years’ experience in heavy civil, natural resources and the E&P industries. He was the founder and founding CEO of Rock Well Petroleum, a private oil & gas company until December 2008 and worked from then until October 2009 forming Laredo Oil. He was employed with Albian Sands as the Manager for the Alberta Oil Sands Projects at Fort McMurray, Alberta, Canada, a joint venture between Shell Canada and Chevron. Mr. See was also President of Oil Recovery Enhancement LLC in Bozeman, Montana, a private oil company. He was selected as one of the top 25 Engineers in North America by the Engineering News Record for his innovations in the petroleum industry. He is a graduate of the Mackay School of Mines at the University of Nevada at Reno, with a degree in Mining Engineering. He is a member of the Society of Mining Engineers and the Society of Petroleum Engineers.

Bradley Sparks currently serves as the Chief Financial Officer and Treasurer of Laredo Oil and has been a director of the company since March 1, 2011. Before joining Laredo Oil in October 2009, he was the Chief Executive Officer, President and a Director of Visualant Inc. Prior to joining Visualant, he was the Chief Financial Officer of WatchGuard Technologies Inc. from 2005-2006. Before joining WatchGuard, he was the founder and managing director of Sunburst Growth Ventures LLC, a private investment firm specializing in emerging-growth companies. Previously, he founded Pointer Communications and served as Chief Financial Officer for several telecommunications and internet companies, including eSpire Communications Inc., Digex Inc., Omnipoint Corporation, and WAM!NET. He also served as Vice President and Treasurer of MCI Communications from 1988-1993 and as Vice President and Controller from 1993-1995. Before his tenure at MCI, Mr. Sparks held various financial management positions at Ryder System Inc. He currently serves on the Board of Directors of Comrise. Mr. Sparks graduated from the United States Military Academy at West Point in 1969 and is a former Army Captain in the Signal Corps. He has a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology and is a licensed CPA in Florida.

Donald Beckham has served as a director of the company since March 1, 2011. Since July 2015, he has been a partner with Copestone Energy Partners LLC. In 1993, he founded Beckham Resources Inc. (“BRI”), which, for over 30 years, has been a licensed, bonded and insured operator in good standing with the Railroad Commission of Texas. Through BRI, Mr. Beckham has drilled and operated fields for his own account. His expertise is in the acquisition, exploitation, exploration and production enhancement of mature oil and gas fields through which he has been able to enhance production by compressor optimization, pump design, work-over programs, stimulation techniques and identifying new pay zones. Prior to BRI, Mr. Beckham was the chief operations manager for Houston Oil Fields Corporation (“HOFCO”), where he began his career. There, he was responsible for drilling, production and field operations and managed approximately 100 people, including engineers, geologists, land men, pumpers, and other contract personnel, as well as state and federal environmental and regulatory functions. He managed an annual capital budget of approximately $30 million and operated approximately 100 wells. HOFCO drilled about 20 wells per annum and performed approximately 30 recompletions and work over operations each year. HOFCO owned interests in about 10 key fields principally in Texas, and company-managed production was approximately 1,000 bpd of crude oil and 10 mm cfd of natural gas. Mr. Beckham is a petroleum engineer and 1984 graduate of Mississippi State University.

Michael Price, an independent director of Laredo Oil, has over 40 years of senior financial and petroleum experience in the global oil and gas industry. He has been a principal in Octagon Energy Advisors, a Houston-based energy investment advisory firm, from 2002 to the present. The firm advises financial institutions and institutional investors participating in energy investments. From 2008 through his retirement in 2021, he was a Managing Director at ING Capital, which provides debt financing to domestic exploration and production companies. From 1998 through 2002, Mr. Price was the Chief Financial Officer of Forman Petroleum Corporation. Before that, Mr. Price was Managing Director at Chase Manhattan Bank for 15 years and was in charge of technical support for Chase’s worldwide energy merchant banking activities. In his early career, he worked as a consulting principal on domestic petroleum engineering and landowner matters and gained extensive international experience working with major oil companies in a variety of operating positions. He holds a BS and MS from Illinois Institute of Technology, an MBA from the University of Chicago, a M.Sc. from the London School of Economics, and an MS in Petroleum Engineering from Tulane University.

FORWARD-LOOKING STATEMENTS

This press release and the statements made by Laredo Oil, Inc. in this press release may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements describe Laredo Oil’s future plans, projections, strategies and expectations, and may be identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or the negative versions of those words or other words of similar meaning. These forward-looking statements are based on assumptions and involve a number of risks, uncertainties, situations and other factors that may cause the actual results, level of activity, performance or achievements of Laredo Oil or the oil industry to be materially different from any future results, level of activity, performance or achievements expressed or implied by these statements. These factors include changes in interest rates, market competition, changes in the local and national economies, and various other factors detailed from time to time in the reports filed with, or furnished to, the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Laredo Oil undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Laredo Oil Inc. (LRDC), closed Thursday's trading session at $0.1591, even for the day. The average volume for the last 3 months is 12,525 and the stock's 52-week low/high is $0.06/$0.2714.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.